A novel triple antibiotic combination offers a potential breakthrough in combatting antibiotic resistance, it is claimed.
Traditional strategies have focused on modifying antibiotics or utilising β-lactamase inhibitors, such as avibactam (AVI), but the efficacy of these is limited against metallo-β-lactamases (MBLs).
This study investigated a triple combination of meropenem (MEM), a serine-β-lactamases (SBL) inhibitor (AVI), and a novel MBL inhibitor [indole carboxylate 58 (InC58)].
The team conducted susceptibility testing on a diverse panel of bacteria producing MBLs and SBLs.
Results revealed that the triple combination exhibited remarkable efficacy against carbapenemase-producing bacteria, extending the spectrum of activity to strains carrying various ββ-lactamases, including oxacillinase-48 (OXA-48), Klebsiella pneumoniae carbapenemase-2 (KPC-2) and New Delhi metallo-ββ-lactamases (NDMs).
Image Credit | iStock
